Introduction
Silibinin, a polyphenolic flavonoid, is a major pure bioactive component in silymarin, which is isolated mainly from the fruits or seeds of milk thistle (Silybum marianum (L.) Gaertn.). Silymarin has been widely used for its anti-hepatotoxic properties for more than three decades in Europe and recently in Asia and the USA (1) . Recent evidence over the past decade has demonstrated that silibinin possesses pleiotropic anticancer capabilities in different tumor cells, including prostate, skin, colon, and bladder cancer models (2) (3) (4) . In in vitro studies, silibinin strongly inhibits cell growth and DNA synthesis to cause cell cycle arrest and apoptotic cell death through an activated caspase cascade (5, 6) . Silibinin is exceptionally well tolerated and largely free of adverse effects (7) and mice fed with silibinin (up to 2 g/kg) do not show any apparent signs of toxicity (8) . Thus, due to its excellent safety profile, anticancer activity, well-known pharmacokinetics and widespread tissue distribution, silibinin has been considered a suitable candidate for cancer chemotherapy and chemoprevention (9) (10) (11) .
Metastasis is a complex process of tumor cell invasion to new tissues, involving the coordination of several signaling pathways that allow changes in cell morphology, changes in adhesion and migration capabilities between the cells and the extracellular matrix (ECM) and changes in cell-cell interaction. Degradation of the ECM by cancer cells is mediated via protease, such as matrix metalloproteinases (MMPs), serine proteinase, and cathepsins. Among these proteases, urokinase-type plasminogen activator (u-PA), which is an upstream enzyme of MMPs, MMP-2 (gelatinase A, 72 kDa) and MMP-9 (gelatinase B, 92 kDa) are the most vital enzymes for the degradation of the main constituent of the basement membrane, type IV collagen (12, 13) , and are therefore deeply involved in cancer invasion and metastasis (14, 15) . Plasminogen activator inhibitor-1 (PAI-1), the major circulating PAI, controls the rate of plasmin generation by forming irreversible inhibitory complexes with u-PA (16) . MMP-2 is activated on the cell surface by a multimeric complex that is composed of MMP-2, membrane type 1 MMP and the tissue inhibitor of metalloproteinase-2 (TIMP-2). The activity of MMP-2 released by osteosarcoma MG-63 cells is significantly increased with interleukin (IL)-6 induction and it is involved in bone remodeling mechanisms (17) . Thus, elucidation of u-PA, PAI-1, MMP-2 and MMP-9 activation mechanism will help understand the process of cell invasion and metastasis (18, 19) . However, the expression of different MMPs depends on unique combinations of different signal transduction pathways in various cells.
The mitogen-activated protein kinase (MAPK) family, the extracellular signal-regulated protein kinases (ERKs), the c-Jun N-terminal kinases (JNKs) and the p38 kinase are unique serine/threonine kinases that are activated via reversible phosphorylation and mediate signal transduction of a wide variety of extracellular stimuli (such as cellcell and cell-ECM adhesion and soluble mediators) into intracellular cascades. MAPKs regulate a number of transcription factors such as activator protein-1 (AP-1) (20, 21) and nuclear factor-jB (NF-jB) (20, 22) , which act independently or coordinately to regulate numerous genes involved in the regulation of u-PA and MMPs expression. Additionally, phosphatidylinositol 3-kinase (PI3K)-Akt signaling plays a prominent role in several processes considered the hallmark of cancer (23) . We have reported previously that u-PA and MMP-2 activities, important determinants of lung cancer cellular invasiveness, were inhibited by silibinin via PI3K-Akt and MAPKs signaling pathways (20, 24) .
Hallmarks of the malignant phenotype are invasion and metastasis events that depend on cell-cell and cell-matrix interactions. Intercellular adhesion restricts cellular migration, invasion, and metastasis and is mainly regulated by the homophilic interaction of cadherin molecules. Malignant cells often down-regulate the levels of E-cadherin, which is anchored to the cytoskeleton via the associated cytoplasmic proteins a-, b-and c-catenins (25) . The cytoskeleton, a complex network of interconnected fibrillar elements, also has been recognized as an important factor in mediating cell-matrix adhesion-independent anddependent signaling (26, 27) . In particular, changes in the organization of the actin cytoskeleton, which are implicated in adhesion-induced, integrin-mediated focal adhesion kinase (FAK) activation, lead to remarkable changes in the tyrosine phosphorylation of several signaling proteins localized at the focal adhesion complex (28) . In addition to regulating cell adhesion to the ECM and regulating the activities of proteolytic enzymes to degrade the basement membrane, integrins activate kinases that phosphorylate cytoskeletal proteins, regulating stress-fiber formation, cellular shape and migration (29) .
Osteosarcoma is the most common primary malignant tumor of the bone, especially in children. An outcome of osteosarcoma generally suggests that 80% of the patients have pulmonary and hepatic metastases (perhaps undetectable) at the time of presentation (30, 31) . Hence, chemotherapy is usually employed as an adjuvant to improve the prognosis and long-term survival. Combination chemotherapy has received more attention in order to find compounds with a known mechanism of action that could increase the therapeutic index of clinical anticancer drugs (19) . In this regard, dietary supplements as well as phytotherapeutic agents (such as silibinin) with high anticancer efficacy and with the least toxicity to normal tissues are suggested as possible candidates to be investigated for their synergistic efficacy in combination with anticancer drugs (32, 33) . The effect of silibinin on cancer invasion and metastasis of osteosarcoma and the underlying mechanisms of such effect remain unclear. Therefore, we tested the hypothesis that silibinin inhibits osteosarcoma MG-63 cellular invasiveness through an ERK/c-Jun-dependent induction of u-PA and MMP-2 expression and activity. We also tested the effect of silibinin on cellular adhesion, changes of cellular shape and suppression of FAK to Raf-ERK signaling pathway.
Materials and methods

Cells and silibinin treatment
Human osteosarcoma MG-63 cells (human male, 14 years old) obtained from the Food Industry Research and Development Institute (Hsinchu, Taiwan) were cultured in minimum essential medium (MEM) (Gibco BRL, Grand Island, NY) supplemented with 10% fetal calf serum, 1 mM glutamine, 1% penicillin/ streptomycin, 1.5 g/l sodium bicarbonate, 0.1 mM non-essential amino acids and 1 mM sodium pyruvate (Sigma, St Louis, MO). The cell cultures were maintained at 37°C in a humidified atmosphere of 5% CO 2 . For silibinin treatment, appropriate amounts of stock solution [0.1 M in dimethyl sulfoxide (Merck, Darmstadt, Germany)] of silibinin (Sigma) were added into culture medium to achieve the indicated concentrations and then incubated with cells for indicated time periods, whereas dimethyl sulfoxide solution without silibinin was used as blank reagent.
Microculture tetrazolium assay
For cell viability experiment, a microculture tetrazolium (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric assay was performed to determine the cytotoxicity of silibinin (34) . MG-63 cells were plated in 24-well plates at a density of 3 Â 10 4 cells per well and silibinin was added at different concentrations (0, 5, 10, 15, 20, 25 and 30 lM) at 37°C for 24 h. After the exposure period, the media was removed, and cells were washed with phosphatebuffered saline (PBS). Then, the medium was changed and cells were incubated with 20 ml microculture tetrazolium (0.5 mg/ml) for 4 h. The viable cell number per dish is directly proportional to the production of formazan, which can be measured spectrophotometrically at 563 nm following solubilization with isopropanol.
Cell invasion and migration assays
Using a modified Boyden chamber invasion assay (24, 35) , we evaluated the effect of silibinin on the invasiveness of MG-63 cells in vitro with or without IL-6 treatment. Matrigel (Collaborative Biomedical Products, Bedford, MA) was diluted to 25 mg/50 ml with cold-filtered distilled water, and applied to 8 lm pore size polycarbonate membrane filters. Cells treated with indicated concentrations of silibinin (0, 5, 10, 15 and 20 lM of silibinin in 50 ll of serum-free medium) were seeded into the upper section of the Boyden chamber (Neuro Probe, Cabin John, MD) at a density of 2.5 Â 10 4 cells per well, and then incubated for 24 h at 37°C. The cells that had migrated to the lower surface of the membrane were fixed with methanol and stained with hematoxylin and eosin. Random fields were counted under a light microscope. For testing the effect of silibinin on cell migration, MG-63 cells were seeded into the Boyden chamber on membrane filters that were not coated with Matrigel. Migration of cells treated or untreated with different concentrations of silibinin was measured as described in the cell invasion assay.
Cell-matrix adhesion assay MG-63 cells (5 Â 10 4 cells per well) treated with different concentrations of silibinin (0, 5, 10, 15 and 20 lM) for 24 h were plated on 24-well dishes coated with type IV collagen and cultured for 30 min. Then, non-adherent cells were removed by PBS washes and adherent cells were fixed with 1% formaldehyde. After a staining with 0.1% crystal violet, fixed cells were lysed in 0.2% Triton X-100 and the absorbance was measured at 550 nm (24, 35) .
Immunofluorescence assay
To determine the effect of silibinin on cell morphology and actin stress fibers, MG-63 cells (8 Â 10 4 cells per well) were plated in six-well plates and grown for 16 h so that they attached to the surface of the plates completely. Silibinin was added to cells at different concentrations (0, 5, 10, 15 and 20 lM) and cells were grown at 37°C in humidified 5% CO 2 for 24 h. After the exposure period, media was removed, and cells were washed with Ca -free PBS for 30 min (blocking) and then with 500 ng/ml tetramethylrhodamine isothiocyanate-phalloidin (Sigma) for 1 h to stain the actin filaments, and the culture plates were examined and photographed by immunofluorescence microscopy.
Casein and gelatin zymography
Casein zymography was used to evaluate u-PA activity in MG-63 cells treated with different concentrations (0, 5, 10, 15 and 20 lM) of silibinin or with 20 lM silibinin for different times (0, 1, 2, 4, 8, 12 and 24 h). Briefly, prepared samples containing 20 lg of total protein were loaded onto a precast 8% sodium dodecyl sulfate-polyacrylamide gel containing 2% casein and 20 lg/ml plasminogen. After electrophoresis, gels were processed as described previously (36, 37) . The non-staining band representing the level of u-PA was measured by spot density measurement using a densitometer (AlphaImager 2000, Alpha Innotech Corp., San Leandro, CA) (38, 39) . MMP-2 and MMP-9 activities were evaluated by gelatin zymography. Briefly, prepared samples containing 10 lg of total protein were loaded onto a precast sodium dodecyl sulfate-polyacrylamide After treatment, cells were rinsed with PBS twice and added with 0.1 ml of cold radioimmunoprecipitation buffer and protease inhibitors, and then scraped. Cell lysates were subjected to a centrifugation of 10 000g for 10 min at 4°C, after a vortex at 0°C for 10 min. For western blot analysis, proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted as described by Chen et al. (20) . The blot was subsequently incubated with 5% non-fat milk in PBS for 1 h to block non-specific binding and then overnight with polyclonal antibodies against u-PA, PAI-1, MMP-2, TIMP-2, FAK, a-catenin, b-catenin, Raf, three MAPKs (ERK 1/2, JNK 1/2 and p38), Akt, c-Jun, c-Fos or Ets-1 or with the specific antibodies for unphosphorylated or phosphorylated activated forms of the corresponding ERK 1/2, JNK 1/2, p38 and Akt. Blots were then incubated with a horseradish peroxidase goat antirabbit or anti-mouse IgG for 1 h. All incubations were carried out at 37°C and intensive PBS washing was performed. After the final PBS washing, signal was developed using the ECL (enhanced chemiluminescence) plus detection kit (Amersham Life Sciences Inc., Piscataway, NJ), and relative photographic density was quantitated by scanning the photographic negatives on a gel analysis system (AlphaImager 2000, Alpha Innotech Corp.).
Reverse transcriptase-PCR and quantitative real-time PCR
Total RNA was extracted from MG-63 cells using a guanidinium chloride procedure. Complementary DNA (cDNA) synthesis and polymerase chain reaction (PCR) amplification were performed as described elsewhere (38) . For reverse transcription, 4 lg of total cellular RNA was used as template in a 20 ll reaction containing 10 lmol deoxynucleoside triphosphates, 25 pmol oligo dT and 200 U reverse transcriptase, and the reaction was performed at 42°C for 1 h. Afterward, 5 ll cDNA product was used as templates in PCR amplifications together with the appropriate primers as described previously (20, 24) . The final products were separated by electrophoresis on 1.8% agarose gels and detected by ethidium bromide staining. Real-time PCR assay was performed as described by Pedersen et al. (40) with the following modification. Specific primers and fluorogenic probes were used for u-PA and MMP-2 genes. For u-PA, MMP-2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), the following forward (F) primers, reverse (R) primers and probes (P) were used: u-PA-F: GAAACCCTACAATGCCCACAGA, R: GACAAACTGCCTTAGGC-CAATC, P: CACAATTACTGCAGGAACCCTGACAAC; MMP-2-F: TCACT-CCTGAGATCTGCAAACAG, R: TCACAGTCCGCCAAATGAAC, P: CAAG-CTTCCCGTTCTCAGCC; GAPDH-F: GAAGGTGAAGGTCGGAGTC, R: GAAGATGGTGATGGGATTTC, P: CAAGCTTCCCGTTCTCAGCC. Primers and probes were designed using the Primer Express 1.0 Software (PE Applied Biosystems, Warrington, UK) and synthesized by PE Applied Biosystems. The cycle threshold (C T ) value was used as an indicator of the amount of target RNA in each sample. Normalized gene expression levels were then calculated using the starting levels of GAPDH in each sample to normalize for differences in total RNA content in the individual samples.
Preparation of nuclear fraction
Nuclear extracts were prepared as described previously (20, 22) . Harvested cells were lysed with buffer A (10 mmol/l 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 10 mmol/l KCl, 0.1 mmol/l ethylenediaminetetraacetic acid, 1.5 mmol/l MgCl 2 , 0.2% Nonidet P40, 1 mmol/l dithiothreitol and 0.5 mmol/l phenylmethylsulfonyl fluoride), followed by vortexing to shear the cytoplasmic membranes. Nuclei were pelleted by centrifugation at 3000 r.p.m. for 30 s at 4°C in a microcentrifuge, and then nuclear proteins were extracted with high-salt buffer B (20 mmol/l HEPES, 25% glycerol, 1.5 mmol/l MgCl 2 , 0.1 mmol/l ethylenediaminetetraacetic acid, 420 mmol/l NaCl, 1 mmol/l dithiothreitol and 0.5 mmol/l phenylmethylsulfonyl fluoride).
Electrophoretic mobility shift assay AP-1-and NF-jB-binding assays in nuclear extracts were performed with biotin-labeled double-stranded AP-1 or NF-jB oligonucleotides (Promega, Madison, WI), and the electrophoretic mobility shift assay was carried out by using the Lightshift kit (Promega). Briefly, binding reactions containing 10 lg of nuclear protein, 10 mM Tris, 50 mM KCl, 1 mM dithiothreitol, 5 mM MgCl 2 , 2 lg poly (dIÁdC) and 2 pmol of oligonucleotide probe were incubated for 20 min at room temperature. Protein DNA complexes were separated by electrophoresis on a 6% non-denaturing acrylamide gel, transferred to positively charged nylon membranes and then cross-linked in a Stratagene crosslinker. Gel shifts were visualized with a streptavidin-horseradish peroxidase followed by chemiluminescent detection.
Transient transfection
MG-63 cells were cultured in MEM with 10% fetal calf serum at 37°C in 5% CO 2 . Cell transfection was carried out using LipofectAMINE 2000 (Invitrogen, Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. Briefly, cells were plated in a 6 cm dish at a density of 3 Â 10 5 cells per well and incubated overnight in MEM supplemented with 10% fetal calf serum. Vectors containing a constructively active mitogen-activated protein kinase kinase 1 (MEK1, designated MEK1EE) cDNA (5 lg), which was kindly provided by Dr Min-Liang Kuo (National Taiwan University, Taipei, Taiwan), were diluted in MEM (500 ll) and then mixed with the transfection solution for 30 min. After washing twice with PBS to remove sera, the cells were incubated with the transfection mixture at 37°C for 4 h and then were allowed to grow in fresh media. Two days after transfection, the cells were used for the following experiment. Collected cells were processed for western blot analysis, gelatin zymography and cell invasion assay.
Statistical analysis
For all of the measurements, analysis of variance followed by Scheffe posteriori comparison was used to assess the differences between control and cells treated with various concentration of silibinin. The Student's t-test was used to analyze the difference between control and silibinin-treated cells after overexpression of constructively active MEK1. Statistical significance was set at P , 0.05.
Results
Cytotoxicity of silibinin on MG-63 cells MG-63 cell viability in the presence of 20 lM silibinin was not significantly different to that of controls in the microculture tetrazolium assay (data not shown) (F 5 1.633, P 5 0.241). Thus, a 24 h treatment with silibinin up to 20 lM had no cytotoxic effect on MG-63 cells, which is consistent with in vitro studies from other laboratories (9-11). Thus, we used this concentration range for silibinin in all subsequent experiments.
Silibinin inhibited the invasiveness and adhesion of MG-63 cells
Silibinin significantly inhibited the invasive activity of MG-63 cells in a dose-dependent manner (.40% inhibition at 20 lM) (P , 0.001) (Figure 1 ). The cell-matrix adhesion assay also showed that silibinin significantly suppressed the adhesive activity of MG-63 cells in a dose-dependent manner (.20% inhibition at 20 lM) (P , 0.001). Unexpectedly, the migration potential of MG-63 cells in the Boyden chamber without Matrigel coating was not affected even when the concentration of silibinin was as high as 20 lM (P 5 0.301).
Silibinin suppressed the expression and activity of u-PA and MMP-2 in MG-63 cells Silibinin reduced the level of u-PA in casein zymography (P , 0.001) and MMP-2 in gelatin zymography (P , 0.001) and in western blotting (P , 0.001) in a dose-and time-dependent manner, but had no effect on PAI-1 (P 5 0.919) and TIMP-2 levels (P 5 0.479) in western blotting (Figure 2A-F) . However, the impact of silibinin on MMP-9 activity was inconclusive because no MMP-9 was expressed in MG-63 cells, even in the absence of silibinin. Reverse transcriptase-PCR analysis showed that silibinin significantly suppressed the messenger RNA expression of u-PA and MMP-2 in MG-63 cells, which was further confirmed by quantitative real-time PCR (P , 0.001) ( Figure 2G and H). The inhibitory effect of silibinin on MMP-2 was stronger than that on u-PA. Besides, silibinin treatment seemed to have more significant effect on the inhibition of MMP-2 enzyme activity than on its protein expression. Therefore, the regulation of u-PA and MMP-2 expression by silibinin in MG-63 cells was transcriptional and post-translational rather than translational. On the other hand, the messenger RNA expression of PAI-1 and TIMP-2 in MG-63 cells was not repressed by any concentration of silibinin examined.
Silibinin induced a change in cell morphology and in actin cytoskeleton arrangement in MG-63 cells After treatment of MG-63 cells with different concentrations (0, 5, 10, 15 and 20 lM) of silibinin for 24 h, actin microfilaments, which were stained with tetramethylrhodamine isothiocyanate-phalloidin (red), distributed heterogeneously and aggregated depending on the treated concentrations ( Figure 3) . MG-63 cells changed morphology and became round and shrunken.
Silibinin inhibited the FAK and Raf expression in MG-63 cells
In western blot analysis, we found that silibinin significantly decreased FAK levels in MG-63 cells in a dose-dependent manner (P , 0.001), but had no effect on a-catenin (P 5 0.114) and b-catenin Silibinin suppress invasion in osteosarcoma levels (P 5 0.590) (Figure 4A and B) . Silibinin, as expectedly, significantly reduced the level of Raf in MG-63 cells (P , 0.001) ( Figure 4C ).
Silibinin inhibited the phosphorylation of ERK 1/2 in MG-63 cells
Western blots showed that silibinin significantly inhibited the phosphorylation of ERK 1/2 in MG-63 cells in a dose-and time-dependent manner (P , 0.001), but had no effect on the phosphorylation of JNK 1/2 (JNK 1: P 5 0.082, JNK 2: P 5 0.078), p38 (P 5 0.858) and Akt (P 5 0.706) ( Figure 5 ).
Silibinin decreased c-Jun/AP-1 activation in MG-63 cells Electrophoretic mobility shift assay showed that silibinin inhibited the DNA-binding activity of AP-1 in MG-63 cells, but not that of NF-jB ( Figure 6A and B) . In western blotting, silibinin significantly inhibited c-Jun levels and its phosphorylation in nuclear extracts of MG-63 cells in a dose-dependent manner (P , 0.001), but had no effects on c-Fos (P 5 0.819) and Ets-1 (P 5 0.195) levels ( Figure 6C and  D) . In contrast, we found that c-Jun levels significantly increased in the cytosolic fractions after silibinin treatment in a dose-and timedependent manner (P , 0.001) ( Figure 6E and F) . Silibinin did not affect the levels of c-Fos (P 5 0.947) and Ets-1 (P 5 0.985) in cytosolic fractions.
Silibinin inhibited the phosphorylation of ERK 1/2 and c-Jun, the activity of MMP-2 and the invasiveness of MG-63 cells with IL-6 induction Western blots showed that IL-6 (50 ng/ml) gradually induced the phosphorylation of ERK 1/2 and reached the plateau at 10 min in MG-63 cells (data not shown). IL-6 also gradually increased the phosphorylation of c-Jun in nuclear extracts of MG-63 cells and reached the plateau at 45 min (data not shown). Thus, we used these two time points, respectively, for IL-6 induction in the subsequent experiments. As expected, silibinin significantly inhibited the phosphorylation of ERK 1/2 in MG-63 cells with 10 min of IL-6 induction in a dose-dependent manner (P , 0.001) ( Figure 7A) . Similarly, silibinin significantly decreased the phosphorylation of c-Jun in nuclear extracts of MG-63 cells with 45 min of IL-6 Silibinin suppress invasion in osteosarcoma induction in a dose-dependent manner (P , 0.001) ( Figure 7B ). We also confirmed that silibinin significantly suppressed the activity of MMP-2 (P , 0.001) and the invasive activity (P , 0.001) of MG-63 cells with IL-6 induction in a dose-dependent manner ( Figure 7C and D). Y.-S. Hsieh et al. which suggests that the target point is the upstream of ERK 1/2. Thus, learning more about the cellular and molecular basis of these different adhesion/invasion processes may help understand how bone tumor cells disseminate, which may lead to new treatment strategies. First, key components of the signaling pathways represent candidate biomarkers that may predict patient outcomes more reliably than traditional morphological criteria; second, understanding the pathways may suggest potential adjuvant targets for inhibiting invasion and metastasis, two major contributors to death among patients with osteosarcoma (30, 31) . In addition, these results are significant because silibinin anti-metastatic capabilities may provide an advantage in combination chemotherapy for osteosarcoma.
For tumor invasion of the basement membrane, MMP-2 is believed to be important because (i) it plays a critical role in the degradation of the ECM, including type IV collagen (12,13); (ii) it is activated in a tumor-specific manner and (iii) its expression correlates with metastatic abilities and poor prognosis (14, 15) . In the present study, treatment with silibinin inhibited the expression of u-PA and MMP-2 in a dose-and time-dependent manner in MG-63, suggesting that this down-regulation of u-PA and MMP-2 contributes to the reduction of the invasiveness of MG-63 cells.
Cell-cell adhesion is an important factor to restrict cellular migration, invasion and metastasis (29) , and reduced expressions of a-and b-catenins have been demonstrated in some cervical cancer cells and metastatic lesions (41) . However, in this study, the level of a-and bcatenins and the migration potential of MG-63 cells were not affected by any concentration of silibinin examined. Intriguingly, silibinin suppressed the cell-matrix adhesion of MG-63 cells, which is the initial and critical step of invasion. After silibinin treatment, the actin microfilaments virtually distributed heterogeneously and aggregated and MG-63 cells became round and shrunken. We therefore wondered what types of adhesion-dependent signaling pathways were involved in these changes of cell adhesion and migration. In addition to its effect on cell migration, FAK is thought to be a key player in integrating both growth factors and adhesion-dependent signals (28) . Because the arrangement of actin cytoskeleton (which anchors to the cell membrane at focal adhesions) was modified by silibinin treatment, we therefore hypothesized that FAK levels would be suppressed. Our findings indicated that FAK and actin filaments are associated in silibinin-mediated inhibition of cell adhesion; therefore, we further explored the downstream regulation of the FAK.
FAK, a 125 kDa protein tyrosine kinase, helps transduce integringenerated signals to the Ras-MAPKs cascades (28, 42) and is overexpressed in a variety of malignancies to regulate the transcription of many MMPs, including MMP-2. FAK autophosphorylation activates Ras, which, in turn, activates PI3K and Raf (43) . PI3K regulates integrin-dependent cell migration by modulating integrin responses in both normal and neoplastic tissue. Raf can lead to MEK and ERK activation, which increases their transcriptional activity (19) . ERK activation is likely to impact invasion and migration through many pathways by influencing gene transcription and survival, as well as by directly regulating the enzymes that are necessary for cell locomotion. Previous research on different cell types has demonstrated that MAPKs like ERK 1/2, JNK and p38 seem to play a central role in regulating the expression of u-PA and MMPs (20, 44) . Thus, inhibition of the MAPKs pathway might prevent angiogenesis, proliferation, invasion and metastasis in a wide range of tumors. In the present study, silibinin certainly inhibited cell invasiveness by reducing the expression and activity of u-PA and MMP-2 through a Raf-ERK-dependent pathway, which targeted the upstream of ERK 1/2, but not via the JNK and p38 signal pathways. FAK may have a dual effect on Raf-ERK-u-PA/MMP-2 signaling invasion and actin cytoskeletonrelated adhesion in silibinin-treated MG-63 cells. Nevertheless, silibinin did not affect the cell migration potential through the PI3K-Akt signal pathway in this study.
Although the MMP-2 promoter does not contain binding sites for NF-jB, c-Jun or c-Fos, it has been reported recently that MMP-2 activation occurs in tumor cells through an AP-1-or NF-jB-dependent pathway (45, 46) . The transcription of MMPs or u-PA gene is regulated by upstream sequences, including motifs corresponding to AP-1-, NF-jB-or Ets-1-binding sites (44, 47) . Our data showed that silibinin inhibits AP-1 DNA-binding activity but not that of NF-jB, which is surprising since silibinin inhibits the invasiveness of human lung cancer cells by activating NF-jB and inhibits angiogenesis of human endothelial cells by down-regulating NF-jB (20, 48) . We also found that, in MG-63 cells, silibinin only depresses the phosphorylation and activation of c-Jun in the nucleus, without affecting c-Fos. This is different to what was observed in A549 cells where silibinin affects both c-Jun and c-Fos activation (20) . These findings suggested that silibinin-mediated inhibition of the transcription factor AP-1 might play a role in the inhibition of MMP-2 or u-PA synthesis, and might occur via a down-regulation of ERK 1/2 activity and expression of c-Jun. Like AP-1 (20,21) and NF-jB (20, 22) , Ets-1 protein is induced by MAPK signaling (49) and interacts with AP-1 and NF-jB Silibinin suppress invasion in osteosarcoma (50) (51) (52) . In this study, silibinin did not inhibit Ets-1 level in MG-63 cells, which suggests that there is no involvement of the ERK/Ets-1 signaling pathway.
Collectively, our data provide an extensive understanding of the effect of silibinin on cell adhesion and invasion, as well as the possible signaling pathway involved in these processes in MG-63 cells. Silibinin prevents MG-63 cell invasion by inhibiting u-PA and MMP-2 through down-regulation of the FAK to Raf-ERK/c-Jun signaling pathway. Silibinin also inhibits MG-63 cell-matrix adhesion by aggregating filamentous actin and changing cellular shape. The dual effect of silibinin may have synergetic effects on cancer invasion and metastasis. These results provide a mechanism for the observed relationship between u-PA and MMP-2 expression and cell invasiveness on the one hand and cell morphology and cell adhesion on the other hand. Targeting the FAK to Raf-ERK/c-Jun pathway may be a potential adjuvant strategy to inhibit the adhesion and invasiveness of this highly metastatic cancer; however, more studies are needed to further justify silibinin as a novel agent with anti-metastatic capabilities in combination chemotherapy against osteosarcoma and other cancers.
